Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.

Journal of experimental & clinical cancer research : CR - 13 Aug 2022

Morra Francesco, Merolla Francesco, Damia Giovanna, Ricci Francesca, Varricchio Silvia, Ilardi Gennaro, Arenare Laura, Califano Daniela, Napolitano Virginia, Fruscio Robert, Melillo Rosa Marina, Palazzo Luca, Celetti Angela

Abstract excerpt

BACKGROUND: Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian cancers (HGSOC) with BRCA1/2 mutations or other deficiencies in homologous recombination (HR) repair mechanisms. However, resistance to PARPi frequently develops, mostly as a result of BRCA1/2 reversion mutations. The tumour suppressor CCDC6 is involved in HR repair by regulating the PP4c phosphatase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystadenocarcinoma, Serous

Share to Cytoskeletal Proteins

Share to Ovarian Neoplasms

Share to Phenotype

Share to Phosphoprotein Phosphatases

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 35964058
DOI: 10.1186/s13046-022-02459-2
PMCID: PMC9375931

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.PMID 35964058Read ↗

Using CCDC6 immunostaining in conjunction with the RAD51 HRD assay as a novel approach to expand PARPi treatment eligibility in HGSOC patientsSemantic proximity Read ↗

Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell deathSemantic proximity Read ↗

Small-Molecule–Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell DeathSemantic proximity Read ↗

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancerSemantic proximity Read ↗

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOCSemantic proximity Read ↗

Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancerSemantic proximity Read ↗

Clinical utility of HRR gene methylation for predicting PARPi sensitivity in HGSOC patientsSemantic proximity Read ↗

Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinomaSemantic proximity Read ↗

C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancerSemantic proximity Read ↗

Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceSemantic proximity Read ↗

Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.